Literature DB >> 3554127

Role of anaerobic beta-lactamase-producing bacteria in upper respiratory tract infections.

I Brook.   

Abstract

Bacteroides sp. (Bacteroides melaninogenicus, Bacteroides oralis and Bacteroides fragilis), peptostreptococci and Fusobacterium sp. are important pathogens in upper respiratory tract infections. A recent increase in numbers of beta-lactamase-producing strains of anaerobic Gram-negative bacteria in upper respiratory tract infections has been associated with increased failure rates of penicillins in eradication of these infections. These infections include chronic otitis media, chronic sinusitis and mastoiditis, chronic recurrent tonsillitis and lung abscesses. The indirect pathogenicity of these organisms is apparent through their ability not only to survive penicillin therapy but also to protect penicillin-susceptible pathogens from the drug. These direct and indirect virulence characteristics of anaerobic bacteria require the administration of appropriate antimicrobial therapy directed against all pathogens in mixed infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3554127     DOI: 10.1097/00006454-198703000-00045

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

1.  Chronic sinusitis.

Authors:  J Steinberg; P Modi
Journal:  Can Fam Physician       Date:  1990-04       Impact factor: 3.275

Review 2.  Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.

Authors:  J A Balfour; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

3.  Detection of conjugal transfer systems in oral, black-pigmented Bacteroides spp.

Authors:  D G Guiney; K Bouic
Journal:  J Bacteriol       Date:  1990-01       Impact factor: 3.490

4.  Acute sore throat and Fusobacterium necrophorum in primary healthcare: a systematic review and meta-analysis.

Authors:  Stefan Malmberg; Susanna Petrén; Ronny Gunnarsson; Katarina Hedin; Pär-Daniel Sundvall
Journal:  BMJ Open       Date:  2021-06-04       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.